Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 14%, reaching a new high of 112.7 HKD, following the announcement of significant research findings related to the antiviral drug VV116 against Nipah virus [1] Company Summary - Wangshan Wangshui was established in 2013, focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - The company announced a licensing and collaboration agreement with Ascletis Pharma in December, granting exclusive rights for the development, manufacturing, and commercialization of VV116 for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [1] Industry Summary - Recent research published by the Wuhan Institute of Virology confirmed that the oral nucleoside drug VV116 has significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly fatal emerging infectious disease [1] - The findings suggest that VV116 could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, offering a ready option for addressing current and future Nipah virus outbreaks [1]
旺山旺水-B一度涨超14%创新高 有研究发现VV116对尼帕病毒有治疗潜力